Skip to main content
FARON PHARMACEUTICALS OY logo

FARON PHARMACEUTICALS OY — Investor Relations & Filings

Ticker · FARN ISIN · FI4000153309 LEI · 7437009H31TO1DC0EB42 IL Manufacturing
Open in API
Filings indexed 626 across all filing types
Latest filing 2026-05-18 Major Shareholding Noti…
Country FI Finland
Listing IL FARN

About FARON PHARMACEUTICALS OY

https://faron.com/

Faron Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies for cancer. The company pioneers macrophage-targeting therapies to leverage the patient's immune system, aiming to address unmet medical needs and improve outcomes. Its lead asset, bexmarilimab, is a first-in-class anti-Clever-1 antibody and a myeloid cell-targeting immunotherapy candidate. Bexmarilimab is being investigated in clinical trials as a potential therapy for hematological malignancies and solid tumors, often in combination with standard-of-care treatments.

Recent filings

Filing Released Lang Actions
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
Major Shareholding Notification Classification · 95% confidence The document is a notification under TR-1/DTR (EU Market Abuse Regulation) disclosing a change in major shareholding (crossing the 3% threshold) by Blood Cancer United, Inc. in Faron Pharmaceuticals. This is a Major Shareholding Notification rather than an earnings release, management report, or proxy statement. It fits the definition of Code MRQ.
2026-05-18 English
Faron to present new BEXMAB translational and clinical data in HR-MDS at EHA 2026
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing the acceptance of a scientific abstract for presentation at a conference and details of an upcoming webcast. It does not contain financial results, board changes, voting matters, legal proceedings, or any formal report or filing. It is a general company announcement distributed via a regulatory news service, fitting the fallback category for miscellaneous regulatory news. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-05-13 English
Faron Pharmaceuticals Ltd: Termination of Liquidity Provision Service
Capital/Financing Update Classification · 95% confidence The document is a company announcement from Faron Pharmaceuticals Ltd dated May 6, 2026, regarding the termination of a liquidity provision agreement with Lago Kapital Oy. It discusses the cessation of a liquidity service and provides contact information and company background. There is no financial data, no report attached or referenced as being published, and no mention of regulatory filings, board changes, dividends, or other report types. The content is an update on a financing-related service (liquidity provision) but does not detail fundraising or capital structure changes directly. Given the nature of the announcement about liquidity provision termination, it fits best under Capital/Financing Update (CAP). The document length is under 5,000 characters, but it is not merely an announcement of a report publication; it is a standalone announcement about a financing-related service termination.
2026-05-06 English
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY
Major Shareholding Notification Classification · 100% confidence The document is a notification of major holdings in Faron Pharmaceuticals Ltd, detailing changes in voting rights and share ownership percentages by Heights Capital Management, Inc. and CVI Investments, Inc. It includes specific data on voting rights percentages, dates of threshold crossing, and financial instruments held. The document is a regulatory announcement about changes in significant share ownership levels, which matches the definition of a Major Shareholding Notification (MRQ). There is no indication that this is a full financial report, audit, or other types of filings. The document length and content confirm it is not a brief announcement or a report publication notice but a substantive notification of shareholding changes.
2026-05-05 English
Faron Pharmaceuticals Ltd: Directorate Appointment
Board/Management Information Classification · 100% confidence The document is a company announcement regarding the appointment of a new non-executive director, Dr. George Stanley Golumbeski, to the board of Faron Pharmaceuticals Ltd. It includes biographical details, current and former positions, and confirms no shareholding in the company. The announcement references compliance with AIM Rules for Companies and Nasdaq First North Growth Market Rulebook, which are regulatory frameworks for disclosures. There is no financial data, no discussion of financial results, no mention of a report or meeting materials, and no indication of voting results or legal proceedings. The content clearly fits the category of Board/Management Information as it announces a change in the company's board of directors.
2026-05-05 English
Faron Pharmaceuticals Ltd: Results of the Annual General Meeting
AGM Information Classification · 95% confidence The document is titled 'Results of the Annual General Meeting' and details the outcomes of the AGM held by Faron Pharmaceuticals Ltd on May 4, 2026. It includes information on shareholder attendance, approval of financial statements, discharge of board and CEO, dividend decisions, board composition and remuneration, auditor appointment, authorization for share issuance, and stock option plans. The content focuses on the decisions and resolutions made during the AGM rather than presenting the full annual report or financial statements themselves. The document length is 8379 characters, which is sufficient for a detailed announcement but does not contain comprehensive financial data or analysis typical of an Annual Report (10-K). Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting, including results and resolutions.
2026-05-04 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.